Pretransplant Panel Reactive Antibodies and Lung Transplant Outcomes in Children

Abstract

Background Pre-lung transplant (LTx) panel reactive antibody (PRA) levels are associated with adverse outcomes in adult LTx recipients, but their impact in pediatric LTx recipients is unknown.

Methods The United Network for Organ Sharing registry was queried from 2004 to 2013 to compare survival between pediatric LTx recipients with PRA class I and II levels = 0 versus > 0.

Results Overall, 333 pediatric LTx recipients had data on class I or II PRA and were included in the analysis. Univariate analysis demonstrated that PRA > 0 was not associated with survival benefit for class I (hazard ratio [HR] = 0.985; 95% confidence interval [CI]: 0.623, 1.555; p = 0.947) or class II (HR = 1.080; 95% CI: 0.657, 1.774; p = 0.762) PRA. Multivariate Cox models confirmed no significant association with mortality hazard for both class I (HR = 1.230; 95% CI: 0.641, 2.363; p = 0.533) and class II (HR = 0.847; 95% CI: 0.359, 1.997; p = 0.704) PRA. Multivariate logistic regression models identified no association between class I or class II and acute rejection within 3 years of LTx.

Conclusions Pretransplant class I and II PRA levels > 0 were not associated with mortality or acute rejection in pediatric LTx recipients.

Keywords

children - cystic fibrosis - human leukocyte antigen - lung transplantation - panel reactive antibody - pediatrics - survival

Funding

No funding was required to complete this work.

• References

• 1 Benden C, Goldfarb SB, Edwards LB , et al; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report—2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33 (10) 1025-1033
• 2 Hayes Jr D, Glanville AR, McGiffin D, Tobias JD, Tumin D. Age-related survival disparity associated with lung transplantation in cystic fibrosis: An analysis of the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2016; 35 (9) 1108-1115
• 3 Hayes Jr D, McCoy KS, Whitson BA, Mansour HM, Tobias JD. High-risk age window for mortality in children with cystic fibrosis after lung transplantation. Pediatr Transplant 2015; 19 (2) 206-210
• 4 Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000; 343 (10) 702-709
• 5 Klein J, Sato A. The HLA system. Second of two parts. N Engl J Med 2000; 343 (11) 782-786
• 6 Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110 (2) 559-562
• 7 Choi JK, Kearns J, Palevsky HI , et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999; 160 (3) 1015-1018
• 8 McManigle W, Pavlisko EN, Martinu T. Acute cellular and antibody-mediated allograft rejection. Semin Respir Crit Care Med 2013; 34 (3) 320-335
• 9 Lau CL, Palmer SM, Posther KE , et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69 (5) 1520-1524
• 10 Shah AS, Nwakanma L, Simpkins C, Williams J, Chang DC, Conte JV. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85 (6) 1919-1924
• 11 Hadjiliadis D, Chaparro C, Reinsmoen NL , et al. Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. J Heart Lung Transplant 2005; 24 (7, Suppl): S249-S254
• 12 Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32 (1) 70-77
• 13 Hayes Jr D, Tumin D, Tobias JD. Pre-transplant panel reactive antibody and survival in adult cystic fibrosis patients after lung transplantation. Lung 2016; 194 (3) 429-435
• 14 Hayes Jr D, Auletta JJ, Whitson BA , et al. Human leukocyte antigen mismatching and survival after lung transplantation in adult and pediatric patients with cystic fibrosis. J Thorac Cardiovasc Surg 2016; 151 (2) 549-57.e1
• 15 United Network for Organ Sharing / Organ Procurement and Transplantation Network Standard Transplant Analysis and Research Database. Available at: http://optn.transplant.hrsa.gov/data/about/OPTNDatabase.asp . Accessed September 6, 2013
• 16 Smith MA, Sundaresan S, Mohanakumar T , et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116 (5) 812-820
• 17 Brugière O, Thabut G, Suberbielle C , et al. Relative impact of human leukocyte antigen mismatching and graft ischemic time after lung transplantation. J Heart Lung Transplant 2008; 27 (6) 628-634
• 18 Wisser W, Wekerle T, Zlabinger G , et al. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant 1996; 15 (12) 1209-1216
• 19 Sundaresan S, Mohanakumar T, Smith MA , et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65 (5) 648-653
• 20 Schulman LL, Weinberg AD, McGregor C, Galantowicz ME, Suciu-Foca NM, Itescu S. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157 (6 Pt 1): 1833-1837
• 21 van den Berg JW, Hepkema BG, Geertsma A , et al. Long-term outcome of lung transplantation is predicted by the number of HLA-DR mismatches. Transplantation 2001; 71 (3) 368-373
• 22 Love RB, Meyer KC, Devito-Haynes LD , et al. Effect of HLA-DR mismatch on lung transplant outcome. J Heart Lung Transplant 2001; 20 (2) 177
• 23 Chalermskulrat W, Neuringer IP, Schmitz JL , et al. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003; 123 (6) 1825-1831
• 24 Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19 (5) 473-479
• 25 Opelz G, Süsal C, Ruhenstroth A, Döhler B. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation 2010; 90 (8) 912-917
• 26 Peltz M, Edwards LB, Jessen ME, Torres F, Meyer DM. HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: implications for donor lung allocation. J Heart Lung Transplant 2011; 30 (4) 426-434
• 27 Krauss RD, Berta G, Rado TA, Bubien JK. Antisense oligonucleotides to CFTR confer a cystic fibrosis phenotype on B lymphocytes. Am J Physiol 1992; 263 (6 Pt 1): C1147-C1151
• 28 Johansson J, Vezzalini M, Verzè G , et al. Detection of CFTR protein in human leukocytes by flow cytometry. Cytometry A 2014; 85 (7) 611-620
• 29 Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant 2014; 33 (2) 127-133